Thank you for your question.
There have, however, been some major investments, notably in AbCellera. The National Research Council of Canada, NRC, received $56 million for the vaccine from CanSino Biologics, which went nowhere. There have been other major investments.
One of the main challenges is not the investment itself, but rather how investments are sent to the right places and how they are monitored.
There's a lot of talk about NRC having to build capacity. This model does not exist in any other country. One federal department waits for approval from another federal department to produce vaccines that, in very few cases, cause serious side effects. There needs to be compensation for people who have these side effects. To my knowledge, the federal government cannot be sued.
I don't know how this model will work. However, it didn't work for ZMapp, by the way.
I hope it will work this time, but we seem, once again, to have put all our eggs in one basket to solve the current crisis.